The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 30, 2013

Filed:

Jul. 13, 2010
Applicants:

Dmitry Dmitrievich Genkin, Saint-Petersburg, RU;

Georgy Viktorovich Tets, Saint-Petersburg, RU;

Viktor Veniaminovich Tets, Saint-Petersburg, RU;

Inventors:

Dmitry Dmitrievich Genkin, Saint-Petersburg, RU;

Georgy Viktorovich Tets, Saint-Petersburg, RU;

Viktor Veniaminovich Tets, Saint-Petersburg, RU;

Assignee:

CLS Therapeutics Limited, Guernsey, Channel Islands, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/43 (2006.01); C12Q 1/34 (2006.01); C12Q 1/68 (2006.01); C07K 14/00 (2006.01); C12N 9/16 (2006.01);
U.S. Cl.
CPC ...
Abstract

The invention is directed to a treatment of diseases that are accompanied by quantitative and/or qualitative changes of blood extracellular DNA and, more particularly, to a treatment of systemic bacterial, fungal and protozoan infections. The inventive method comprises introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic infection caused by bacteria, fungi or protozoa, wherein said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNase enzyme: said agent being administered in doses and regimens which are sufficient to decrease the average molecular weight of circulating extracellular blood DNA in the blood of said patient; such decrease in the average molecular weight can be measured by gel electrophoresis of extracellular blood DNA fraction from the blood of said patient. A DNase enzyme may be applied in a dose and regimen that provide a DNase DNA hydrolytic activity measured in blood plasma that exceeds 1.5 Kunitz units per 1 ml of blood plasma for more than 12 hours within a period of 24 hours.


Find Patent Forward Citations

Loading…